JUL 07, 2016 04:11 PM PDT

Integrated Genomic and Proteomic Approach for Ovarian Cancer

WRITTEN BY: Cassidy Reich
Ovarian cancer accounts for 3% of all cancers among women and is the 5th leading cause of cancer deaths for women in the U.S. The most aggressive form of ovarian cancer, the high-grade serous carcinoma (HGSC), accounts for 70% of ovarian cancer cases. Only 1 in 6 patients lives 5 or more years after diagnosis with an HGSC.

                 Ovarian cancer is the 5th leading cause of cancer death among women.
A very innovative, collaborative effort between groups at Johns Hopkins and the Pacific Northwest National Laboratory combined genomic and proteomic data from a total of 169 ovarian tumors. This approach is so innovative because cancer is usually considered a disease of the genome, with mutated genes being expressed as oncogenic, dysfunctional proteins. However, looking at complete profile of expressed proteins, known as the proteome, provides even more insights into disease pathology than just looking at the genome.

The Johns Hopkins team analyzed a set of ovarian tumor samples that had previously sequenced by The Cancer Genome Atlas (TCGA) that they chose based on their degree of homologous recombination deficiency and characterized by mutations in BRCA1, BRCA2, or PTEN. Mutations in these genes is also well-known to cause breast cancer, as well as increase cancer risk and severity. By looking at ovarian tumors with the same mutations as some breast cancers, the researchers were hoping to find enough similarities in the functional proteomes of these two cancers to open the door to the possibility of ovarian cancer patients receiving the same drug regimen that breast cancer patients have.

The other team in the study based at Pacific Northwest National Laboratory looked at another set of ovarian tumors that had also been sequenced by TCGA. Instead of looking at samples with certain mutations or deficiencies, their strategy was to search for biological factors that could contribute to survival time.

Using mass spectrometry, the two teams identified 3586 proteins common to all of the 169 tumors analyzed. Sifting through all these proteins was obviously a massive undertaking, but it provided many novel insights into the aggressive HGSC. A characteristic of cancer in general, but particularly of HGSCs, is the appearance of copy-number variations. Through this massive proteogenomic experiment, the two teams identified sections of chromosome 2, 7, 20, and 22 that were prone to increased copy-number and lead to increased expression of more than 200 proteins. Many of these overexpressed proteins are involved in cell movement and immune system function; both of the processes are very connected to cancer progression.

The researchers also saw that the very diverse genome rearrangements of the different samples converged on similar signaling pathways. And for the main goal of the team from Pacific Northwest National Laboratory, they were able to identify certain signaling pathways that were associated with short survival. These results would not have been possible to find by just looking at the genome, proving the importance of the proteome in cancer research.

Sources: EurekAlert and Cell
About the Author
  • Cassidy is a curious person, and her curiosity has led her to pursue a PhD in Pharmacology at the New York University Sackler Institute of Biomedical Sciences. She likes to talk about science way too much, so now she's going to try writing about it.
You May Also Like
JUN 27, 2018
Cancer
JUN 27, 2018
Engineered Poliovirus in Clinical Trials for Glioblastoma
Glioblastoma is a very difficult cancer to treat; researchers look to an engineered poliovirus for novel targeted approach for grade IV patients....
JUN 27, 2018
Infographics
JUN 27, 2018
The Role of Biomarkers In Modern Medicine
A biomarker (short for biological marker) is a measurable indicator of some biological state or condition. The biomarker can be measured objectively and consistently. Biomarkers play signific...
JUL 12, 2018
Infographics
JUL 12, 2018
3D Imaging Advantage
Learn about the advantages and the technology behind 3D cellular image acquisition and analysis with this infographic from Molecular Devices....
AUG 14, 2018
Cancer
AUG 14, 2018
Can Zika Virus Help Neuroblastoma Patients?
Researchers in Florida published the potential for Zika virus to help in the treatment of Neuroblastoma in patients of all ages....
SEP 13, 2018
Cancer
SEP 13, 2018
Breast tumors can stop their own metastasis
According to the American cancer society, metastatic breast cancers or stage 4 breast cancers have 5-years survival rate of 22% which is lower than at early stages. Metastatic breast cancer...
OCT 21, 2018
Technology
OCT 21, 2018
New Technology Detects Early-Stage Lung Cancer
According to recent research published in the Journal of Molecular Diagnostics, outcomes of patients with non-small-cell lung carcinoma (NSCLC) may be impr...
Loading Comments...